Published in AIDS Weekly, April 5th, 2004
In a recent study, scientists in Tennessee "sought to determine the risk of acquired rifamycin-resistant (ARR) tuberculosis associated with rifampin-versus rifabutin-based directly observed therapy and to assess the risk factors for relapse of tuberculosis."
"This observational cohort study included patients with culture-confirmed rifamycin-susceptible tuberculosis reported to the Baltimore City Health Department (Baltimore, MD) during the period of January 1993 through December 2001," explained R.E. Nettles and coauthors at Vanderbilt University. "Of the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.